

行政院國家科學委員會專題研究計畫 成果報告

抗腫瘤藥物 Cisplatin 與含 thio 化合物相互作用之氧化還
原效應

計畫類別：個別型計畫

計畫編號：NSC91-2113-M-038-003-

執行期間：91年08月01日至92年07月31日

執行單位：臺北醫學大學醫學研究所

計畫主持人：陳建志

計畫參與人員：林俊茂

報告類型：精簡報告

報告附件：出席國際會議研究心得報告及發表論文

處理方式：本計畫可公開查詢

中 華 民 國 92 年 12 月 26 日

行政院國家科學委員會補助專題研究計畫**成果報告**

抗腫瘤 cisplatin 與 thio 化合物的作用與 Isovitexin 在巨噬細胞抑制 LPS-mediated 誘導 nitric oxide synthase and cyclooxygenase

計畫類別：個別型計畫

計畫編號：NSC 91 - 2113 - M - 038 - 003

執行期間：91 年 8 月 1 日至 92 年 7 月 31 日

計畫主持人：陳建志

共同主持人：林俊茂

計畫參與人員：黃豪銘 王淑慧

成果報告類型(依經費核定清單規定繳交)：精簡報告

本成果報告包括以下應繳交之附件：

赴國外出差或研習心得報告一份

赴大陸地區出差或研習心得報告一份

出席國際學術會議心得報告及發表之論文各一份

國際合作研究計畫國外研究報告書一份

處理方式：除產學合作研究計畫、提升產業技術及人才培育研究計畫、列管計畫及下列情形者外，得立即公開查詢
二年後可公開查詢

執行單位：台北醫學大學醫學研究所

中 華 民 國 92 年 9 月 1 日

摘要

Cisplatin and thio-compound

Cisplatin binding DNA to generate superoxide and hydroxyl radical is proposed due to the formation of platinum (Pt)-DNA complex which iron ion catalyzes the reaction; whether platinum reacting with hydrogen peroxide to generate Fenton like reaction or platinum only promoting the Fenton reaction still need more work. The cytotoxicity induced by cisplatin could be reduced by antioxidants. Glutathione depletion was observed on the effects of cisplatin where could be reduced by reacting with lipoate or amifostine. The chloride of cisplatin could exchange with thio-group of lipoate or amifostine to form a complex; meanwhile, selenium also form a $(\text{NH}_3)_2\text{Pt}(\text{SeO}_3)$ complex to reduce the toxicity of cisplatin. The structure of those complex will still need some experiments to illustrate a highly capability to induce the generation of free radicals.


Isovitexin and iNOS

Isovitexin and related flavonoids isolated from rice hull of *Oryza sativa* have been identified with strong antioxidant activity. We investigate the effect of isovitexin on the activities of inducible cyclooxygenase (COX-2) and inducible nitric oxide synthase (iNOS) in lipopolysaccharide (LPS)-activated RAW 264.7 macrophages. Isovitexin's antioxidant activity was proved to be a potent protection against DNA damage induced by Fenton reaction. Moreover, isovitexin significantly scavenged the excess hydrogen peroxide induced by LPS. Treatment of cells with isovitexin markedly reduced LPS-stimulated NO and prostaglandin production, in a concentration-dependent manner, with an IC_{50} of about 58.5 and 80.0 μM , respectively. The expression of both iNOS and COX-2 were also inhibited by isovitexin treatment. Transient transfection experiment showed that isovitexin suppressed iNOS promoter and NF- κ B-dependent transcriptional activities. In Addition, western blotting analysis revealed that isovitexin prevented degradation of I κ B-alpha and translocation of NF- κ B from the cytoplasm into the nucleus. Our results clearly demonstrate that suppression of ROS-mediated NF- κ B activity by isovitexin may be beneficial in reducing the development of inflammation.

前言

Cisplatin and thio-compound

臨床上抗腫瘤化學治療，經常合併使用抗代謝抗腫瘤藥物 (anti-metabolites) 和 alkylating agent，以減低細胞毒性，提高療效，5-FU (5-fluorouracil) 和 Cisplatin (cis-diamminedichloroplatinum (II), DDP) 便是一個常用第一線的組合。從自由基醫學的研究上，過去我們的實驗發現 5-FU 與氫氧自由基反應，具有保護去氧核糖核酸免於攻擊的能力；而其他 Cisplatin 的實驗發現，Cisplatin 媒介產生超氧自由基(O_2^-)及氫氧自由基，產生細胞毒性。兩者之合用，雖然作用標的分子不同，在細胞內顯然功能互相抵銷，其細胞生物學上的功能，尚待研究；生化學上，分子相互作用之涵義，亟待本計畫的探討。



5-FU 是臨床上最普遍使用的一種抗代謝抗腫瘤藥物，其結構與 uracil 相似，因為我們的實驗發現 5-FU 具有保護去氧核糖核酸，免於受到氫氧自由基的攻擊的能力。不同濃度的 5-FU 與 0.35% H₂O₂ 與 40 μ M 的鐵離子 37 30 分鐘反應，去氧核糖核酸(DNA)的片段化 (fragmentation) 減少。在相同濃度下(2.0mM)，5-FU (仍有 70% 超螺旋型質體) 保護去氧核糖核酸，免於受到氫氧自由基的攻擊比 Phenylalanine (30%) 好。5-FU 亦具抗脂質過氧化作用，malondialdehyde (MDA) 產生隨 5-FU 濃度的增加，在濃度為 10mM 時，linolenic acid 氧化程度降低約 60%。顯示 5-FU 的角色已超出抗腫瘤化學治療之抗代謝抗腫瘤藥物的範疇，應該重新賦予新的細胞生理的詮釋。目前我們正在執行本年度計畫，探討 5-FU 經 Fenton reaction 的產物 mw144 是何？分析 5-FU 進行 Fenton reaction 的產物，發現在毛細管電泳實驗中，滯留時間約為 6.06 分鐘，新生成物隨著 Fe(II) 的濃度增加而增加。氣相層析質譜儀 (GC/MS) 分析，生成物滯留時間為 7.20 分鐘，分子量 144 (mw144)。¹H NMR 的變化發現 C₆-H 隨著反應時間的增加而減少，¹³C NMR 出現新生成了 77.5 與 152 波峰。根據分子離子峰(Molecular ion peak)的分布解析，生成物 mw144 結構可能為 5FU-epoxide (C₄N₂HO₃F) 或 5,6-dihydroxyluracil (diOHU, C₄N₂H₄O₄) 或 N-formyl-N-oxoacetyl urea (FOU, C₄N₂H₄O₄)，其相關抗自由基與抗代謝抗腫瘤功能之探討正在進行中。

Cisplatin 與去氧核糖核酸實驗發現產生超氧自由基(O_2^-)及氫氧自由基，其產生自由基之機制被認為，Cisplatin 與 DNA 結合形成 platinum (Pt) 與 DNA 複合體，誘發自由基產生，鐵離子催化其反應，是否經由 platinum 與過氧化氫(H₂O₂) 發生 Fenton-like reaction，或 platinum 僅加強 Fenton- reaction 的強度並不清楚 其細胞毒性可經由 antioxidants, 如 vitamin C、curcumin、N-acetylcysteine 作用而減輕，指出 Cisplatin 的作用機制的確誘發自由基產生。Platinum analogs 化合物之誘發自由基，亦由 Cisplatin 之類似化合物 Carboplatin 實驗證實。

唯發現 Cisplatin 的作用常伴隨 glutathione depletion, 其中若添加 lipoate 或 amifostine (兩者均含 free thiol), 可減少 glutathione depletion, 因此推測 Cisplatin 的氯離子會與含 thio 化合物的-SH 交換, 形成錯化合物 GS-Pt, Lipoate-Pt 或 WR1065-Pt [32]。錯化合物的生成, 是否具有高度誘發自由基的能力, 不甚清楚; 顯然這個途徑並非 glutathione 例行的解毒機制, 因為造成 glutathione 減少, 過氧化氫無法清除, 脂質過氧化增加[33], 可能是 glutathione

降低，使 Glutathione Peroxidase 無 glutathione 用於清除過氧化氫所致。

前述現象亦被認為還原 glutathione 的 Glutathione Reductase 之輔因子硒離子會降低 glutathione 的損失[34]，其原因可能是加強 glutathione 的還原，或是硒離子與 Cisplatin 形成 $(\text{NH}_3)_2\text{Pt}(\text{SeO}_3)$ 錯化合物，降低些許的氧化壓力[35]，可能因此減低 Cisplatin 的毒性，原理也不清楚。Cisplatin 的作用中誘發自由基產生，鐵離子催化其反應的機制，需要釐清的是那一個反應機構誘發自由基產生？

Isovitexin and iNOS

The toxicity ascribed to the superoxide radical is believed caused by superoxide's direct interaction with biological targets. Reactive oxygen species (ROS) can initiate a wide range of toxic oxidative reactions [1]. Oxidative stress has been implicated in an enormous variety of physiological and pathological processes, including aging, cancer, diabetes mellitus, atherosclerosis, neurological degeneration and arthritis. Antioxidant treatment can prevent the organ injury associated with ROS [2,3]. Hydrogen peroxide is a mediator of inflammation via NF κ B pathway activation [4]. Prostaglandin biosynthesis and nitric oxide production have been implicated in the process of carcinogenesis and inflammation. Prostaglandins, especially prostaglandin E₂ (PGE₂), affect cell proliferation, tumor growth, and suppress the immune response to malignant cells. Therefore, high levels of prostaglandins could favor malignant growth [5]. Two isozymes, designated COX-1 and COX-2, have been identified, and each are encoded by separate genes. The COX-1 isozyme is believed to be a housekeeping protein in most tissues and seems to catalyze the synthesis of prostaglandins for normal physiological functions. COX-1 is expressed at essentially constant levels and does not fluctuate in response to various stimuli. In contrast, COX-2 is rapidly induced by tumor promoters, growth factors, cytokines, and mitogens in various cell types [6]. Many cell types associated with inflammation, such as macrophages, endothelial cells and fibroblasts, express the COX-2 gene upon induction [7]. Nitric oxide (NO) is released by a family of enzymes, constitutive NO synthase and an inducible NO synthase (iNOS), with the formation of stoichiometric amounts of L-citrulline from L-arginine. iNOS-mediated excessive and prolonged NO generation has attracted attention because of its relevance to epithelial carcinogenesis. NO has been reported to cause mutagenesis and deamination of DNA bases and to form carcinogenic *N*-nitrosoamines [8]. With respect to the role of NO in the post-initiation phase, it should be noted that it plays important roles in such inflammatory responses as edema formation and hyperplasia, as well as in papilloma development in mouse skin. NO is also involved in the production of VEGF, the overexpression of which induces angiogenesis, vascular hyperpermeability, and accelerated tumor development [9]. NO can stimulate tumor growth and metastasis by promoting the migratory and invasive abilities of tumor cells, which may also be triggered by activation of cyclooxygenase (COX)-2. Treatment of TPA in mice led to edema and papilloma formation by enhancing COX-2 protein expression. Specific COX-2 inhibitors could counteract these biological events. Suppression of enzyme induction and the activities of iNOS/COX-2 is a new paradigm for the prevention of carcinogenesis in several organs. Thus, selective inhibitors of iNOS, COX, or both may have a therapeutic role in certain cancers [10].

The active form of NF- κ B is composed mainly of two proteins: p65 and p50. In unstimulated cells, NF- κ B exists in the cytosol in a latent form bound to its inhibitory protein, I κ B. After stimulating the cells with various agents, I κ B becomes phosphorylated and subsequently succumbs to proteolytic degradation. Releasing I κ B from NF- κ B complex allows the activation and nuclear accumulation of the active NF- κ B subunits [11,12]. The NF- κ B family of transcription factors regulates expression of many genes, including the iNOS gene, involved in immune and inflammatory responses. The promoter region of the murine gene encoding iNOS contains two NF- κ B binding sites, located at 55 and 971 base pairs upstream from the TATA box [13]. The binding of the potentially relevant transcription factor, NF- κ B, to the κ B sites has been shown to be functionally important for iNOS induction by LPS [14]. At least three different signal transduction pathways to trigger iNOS mRNA expression in 3T3 cells were reported. All these pathways seem to converge in the activation of the essential transcription factor, NF- κ B

[15-17]. It has been proposed that reactive oxygen species are involved in the activation of NF- κ B via regulation of various redox-sensitive protein kinases or tyrosine kinases [18-20]. Antioxidants such as (-)-epigallocatechin-3-gallate (EGCG) [21], resveratrol [22], aspirin [23] and naturally occurring flavonoids [24], have been reported to suppress NO production, and their inhibition mechanisms are based on their ability to inhibit the activation of NF- κ B.

Rice possesses special dietary importance in Asia, where the incidence of breast and colon cancer is markedly lower than that in the western world [25]. Some investigations of potential beneficial effects of specific rice constituents exhibiting effects on prevention or amelioration of malignant disease have been conducted [26]. It has been reported that rice constituents counteract chemical-induced mutagenicity, tumor promotion, and carcinogenicity [27,28]. However, little is known about which specific molecules may be responsible for these activities. A number of mechanisms have been proposed by which such agents suppress tumors, but they all culminate in interference with the proliferation and survival of initiated cells [29]. Constituents from rice bran have been found to be beneficial for cancer prevention by epidemiological survey. Rice bran contains several classes of chemopreventive agents, *e.g.*, flavonoids and their glycosides, tocotrienols, and γ -oryzanol. Isovitexin and related flavonoids were isolated from rice hull of *Oryza sativa* and identified to have strong antioxidant activity [30,31]. Furthermore, xanthine oxidase inhibition, DNA protection, and prevention of heavy-metal-induced cell damage by isovitexin were described in our laboratory [31]. Here, we further evaluate the antioxidative properties of isovitexin, and examine the production of PGE₂ and NO from mouse macrophages. The molecular mechanisms of the reduction of iNOS and COX-2 expression and NF- κ B activation in LPS-stimulated RAW 264.7 cells were further explored. The present data suggest that isovitexin could protect against endotoxin-induced inflammation by suppression of COX-2 and iNOS activation.

結果與討論

Cisplatin and thio-compound

在 DNA fragmentation 實驗裡 Cisplatin 隨著濃度增加，破壞 DNA 的程度越高。Fenton reaction 產生氫氧自由基，破壞 DNA 的程度不如預期，相反的 Fenton reaction 的氫氧自由基，似乎被 Cisplatin 所吸收。還原 glutathione 的 Glutathione Reductase 之輔因子硒離子會降低 glutathione 的損失，其原因可能是加強 glutathione 的還原，或是硒離子與 Cisplatin 形成 $(\text{NH}_3)_2\text{Pt}(\text{SeO}_3)$ 錯化合物，降低些許的氧化壓力，可能因此減低 Cisplatin 的毒性，上述原理尚待追查。Cisplatin 的作用中似乎誘發自由基產生，鐵離子催化其反應(Masuda et al,1998 ; Radhakrishna et al, 1998)的機制並不在本實驗裡觀察得到，需要釐清，但 Cisplatin 的 platinum 反應似乎優先誘發自由基產生，造成 DNA fragmentation 破壞 DNA，可能經由 DNA 結合形成 Pt-DNA 複合體。GS-Pt、Lipoate-Pt、WR1065-Pt 或 $(\text{NH}_3)_2\text{Pt}(\text{SeO}_3)$ 等錯化合物的形成，尚待鑑定。這個反應機制可能是單純的電子生成器度(electron generator)，只要有適當的接受者，可以形成各種自由基，因為 Platinum analogs 誘發不僅產生超氧自由基(O_2^-)及氫氧自由基的生成；在 pH2.8 及 8.5 時亦誘發 tryptophan 自由基(Zang and Rodgers, 1999)。鐵離子催化 Cisplatin 誘發自由基產生的反應，可能過氧化氫參與其中，推動 Fenton-like reaction，為細胞外的反應，過氧化氫是否優先選擇鐵離子是一個未知問題。

Isovitexin and iNOS

Protection of supercoiled DNA from hydroxyl radical damage by isovitexin.

Hydroxyl radical ($\cdot\text{OH}$) generated by the Fenton reaction is known to cause oxidative induced DNA strand breakage to yield an open circular DNA (relaxed circular DNA) under biological conditions. The hydroxyl radical scavenger property of isovitexin or related flavonoids on reducing the supercoiled DNA strand breakage caused by hydroxyl radical was evaluated. Fig. 2A is the result obtained from an agarose gel of pUC-19 plasmid DNA that was subjected to Fenton reaction in the absence or presence of flavonoids. Supercoiled DNA migrates faster than relaxed circular DNA in agarose gel electrophoresis. DNA strand breakage could be induced *in vitro* in the presence of H_2O_2 and Fe^{2+} (lane 4). Treatment of DNA with the ascorbic acid, α -tocopherol, or flavonoids was tested, and the percentage of relaxed form DNA was quantified in a lower panel. These results showed that the percentage of relaxed form DNA was reduced from 83.6% to 42.5% in the presence of isovitexin, which is the most effective agent among the test compounds for reducing DNA relaxation. Genistein, quercetin, and kaempferol showed comparable antioxidative activity in this assay system. These results suggest that isovitexin reacted with and/or scavenged the hydroxyl radicals and reduced the DNA damage in the tested system.

Isovitexin lowers LPS-activated cellular hydrogen peroxide in Raw 264.7 macrophage cells

Green DCF fluorescence is generated when DCF-DA is hydrolyzed by esterase and is oxidized by hydrogen peroxide. The FL1-H fluorescence intensity on a FACScan flow cytometer reflects the hydrogen peroxide concentration in living cells. The hydrogen peroxide concentration of Raw 264.7 cells was elevated upon LPS treatment (100 ng/ml) for 30 min. Isovitexin added prior to LPS treatment reduced the concentration of hydrogen peroxide in living cells (Fig. 2B). The FL1-H intensity of untreated cells increased in 30 min upon LPS treatment, whereas the LPS-induced intensity of isovitexin-treated cells (5, 10, 20 μM respectively) was suppressed in a dose-dependent manner. Isovitexin, with the ability to lower LPS-activated cellular hydrogen peroxide, possesses the potential to reduce oxidative stress in RAW 264.7 macrophage cells.

Isovitexin decreased LPS-induced NO production and iNOS expression in activated macrophages

The half-life of NO is very short, so we used nitrite production as an indicator of NO released in LPS-activated macrophage to investigate the anti-inflammatory effects of isovitexin. The concentration-response relationships were determined 18 h after treatment with LPS

(50 ng/ml) alone or in the presence of isovitexin. Isovitexin was found to reduce NO generation in a concentration dependent manner (Fig. 3A). Isovitexin reduced NO generation with an IC₅₀ about 58.5 μM. Cell viability assay verified that the inhibition by isovitexin was not due to general cellular toxicity (data not shown). The isovitexin dissolved in DMSO did not interfere with the Griess reaction. The protein levels of iNOS upon isovitexin treatments in activated macrophage cells were evaluated. RAW 264.7 cells maintained under normal conditions express slightly detectable levels of iNOS protein. After stimulation with LPS, the level of iNOS protein level increased. Inhibition of iNOS protein by isovitexin was detected in a concentration-dependent manner after 18 h treatment. The relative level of iNOS protein after treatment with 25, 50, 75, and 100 μM isovitexin was 0.86, 0.64, 0.38, and 0.13, respectively, versus LPS alone (Fig. 3B). The β-actin with constant expression was an internal control. The inhibitory concentration for iNOS protein expression was similar to that for the reduction of nitrite formation. In order to investigate whether the suppression of iNOS protein by isovitexin was due to reduced iNOS mRNA expression, a RT-PCR analysis for total mRNA samples, extracted from RAW 264.7 cells after 8 h treatment, was carried out. The amplification of cDNA with primers specific for mouse iNOS and GAPDH (as control gene) is shown in Figure 3C. The results indicate that lower levels of iNOS mRNA were expressed in the presence of isovitexin in LPS-activated macrophages. The data suggest that isovitexin modulated iNOS expression at the transcriptional level. Consistent with previous findings, isovitexin suppressed iNOS gene expression, thus inhibiting the production of NO in LPS-stimulated RAW 264.7 cells. To further investigate the importance of LPS and isovitexin in modulating expression of iNOS, transient transfection was performed using mouse iNOS promoter-driven luciferase construct. LPS-induced iNOS promoter activity was inhibited by isovitexin (Fig. 3D). The luciferase activity from LPS-activated cells was a 10.81-fold induction, which was suppressed to 3.47 fold by isovitexin. Therefore, isovitexin might block LPS-mediated inflammation via signaling.

Isovitexin decreased LPS-induced PGE₂ production and COX-2 expression in activated macrophages

Several studies in inflammation models have shown reciprocal interactions between NOS and cyclooxygenase pathways, most of which show stimulation of COX-2 by NO. Conversely, NOS enzymes can also be modulated by cyclooxygenase products. The concentration-response relationships were determined 18 h after treatment with LPS (50 ng/ml) alone or in the presence of isovitexin. Isovitexin showed reduction of PGE₂ generation in a concentration dependent manner with an IC₅₀ about 80.0 μM (Fig. 4A). The inhibition was not due to general cellular toxicity (data not shown). COX-2 protein in activated cells was also suppressed by isovitexin in a concentration-dependent manner after 18 h treatment. The relative level of COX-2 protein with the treatment of 20, 40, 60, 80, and 100 μM isovitexin was 1.02, 0.82, 0.80, 0.71, and 0.58, respectively, versus LPS alone (Fig 4B). PGE₂ production and COX-2 protein level exhibited less interference by isovitexin than that of NO and iNOS in activated macrophages.

Suppression of LPS-induced NF-κB activation by isovitexin in RAW 264.7 cells

It has been documented that the transcription factor NF-κB is involved in the activation of iNOS by LPS induction. It needs to be asked whether isovitexin perturbs the translocation of NF-κB into the nucleus. Nuclear and cytosolic fractions of LPS-activated cells with time courses (0, 15, 30, 60 min, respectively) were prepared and subjected to immunoblot analysis. The amounts of nuclear p65 significantly increased during the 60-minute course, during which the cytoplasmic fraction decreased (Fig. 5A). Co-incubation with LPS plus isovitexin resulted in the reduction of nuclear content of p65 protein, which was almost all retained in the cytoplasm. Thus, isovitexin is able to block LPS-mediated NF-κB nuclear translocation and activation. To further confirm the result, NF-κB promoter-driven luciferase reporter gene (pNFκB-Luc) was transiently expressed in activated cells. The luciferase activity from LPS-activated cells was a 5.51-fold elevation, which was suppressed to 2.84 fold by isovitexin (Fig. 5B). The LPS-induced NF-κB promoter activity was inhibited by isovitexin. Therefore, isovitexin blocks LPS-mediated inflammation via NF-κB signaling.

Inhibitory effects of isovitexin on LPS-induced degradation of I κ B α

Since LPS-mediated activation of NF- κ B results from the hyperphosphorylation of I κ B α and its subsequent degradation, we examined the I κ B α protein levels in activated macrophages. Cytosolic fraction of LPS-activated cells with time courses (0, 15, 30, 60 min, respectively) were prepared and subjected to immunoblot analysis. I κ B α protein was detected by anti-I κ B α antibody. Upon stimulation with LPS, the amounts of I κ B α decreased during the 60-min time course, while isovitexin treatment resulted in maintaining fairly constant I κ B α protein level (Fig. 5C). It can be suggested that inhibition of NO production by isovitexin occurs via blocking the phosphorylation, as well as degradation of I κ B α protein, thus preventing the activation and translocation of NF- κ B to the nucleus.

It is widely believed that oxidative DNA damage over the long human lifespan is a significant contributor to the development of the major cancers. Diet or chemopreventive agents that decrease oxidative DNA damage could delay or prevent the onset of cancer. ROS released by phagocytic cells are involved in the link between inflammation and cancer. Excessive and persistent formation of ROS by inflammatory cells is thought to be a key factor in the genotoxic effect. Different ROS affect DNA in different ways. It is believed that most of the H₂O₂-mediated DNA damage is due to the production of hydroxyl radical via the Fenton reaction [39]. Hydroxyl radical generates a multiplicity of products from all four DNA bases. The most commonly produced base lesion is 8-hydroxyguanine, which is often used as an index of oxidative DNA damage [40]. In addition, free radical-mediated reactions can cause multiple lesions and activate the nuclear enzyme poly(ADP-ribose) synthetase (PARS) (a protein modifying and nucleotide-polymerizing enzyme also known as PARP). PARS-related suicide pathway might play a role in various pathophysiological conditions in vivo [1]. In our study, isovitexin showed effective DNA-protection activity, i.e., effectively inhibiting pUC19 DNA strand break induced by the Fenton reaction. This compound, with the ability to protect DNA from the hydroxyl radical damage, may suppress oxidative DNA damage and/or the DNA damage-mediated signaling pathways, which involve various forms of cellular injury.

Persistent inflammation is a significant risk factor for several types of cancer. Inflammation can be a significant source of oxidative damage. Activated macrophages and neutrophils release a number of ROS, including H₂O₂, nitric oxide, superoxide, and hydroxyl radical, all of which can damage the DNA of nearby cells. H₂O₂ is produced by a variety of intracellular reactions upon stimuli [41]. The intracellular source of H₂O₂ is elevated by the activation of NAD(P)H oxidase, xanthine oxidase, and respiratory burst [42,43]. ROS was first proposed to be the common second messenger for activation of NF- κ B by Schreck [44]. H₂O₂ has also been shown to activate NF- κ B in Hela cells. In another study, H₂O₂ has been implicated in platelet-derived growth factor signal transduction involving p42/p44 mitogen-activated protein kinase, and JNK activation. The model was therefore proposed whereby diverse agents all activated NF- κ B by causing oxidative stress [45]. Antioxidants, such as N-acetylcysteine, pyrrolidine dithiocarbamate, vitamin E, and vitamin C have been used to inhibit NF- κ B activation in response to diverse stimuli [46]. The signaling pathway-mediated inflammation was proposed based on our studies, in which the LPS triggers protein kinase C activity, hydrogen peroxide production, MAP kinase activated I κ B phosphorylation, and NF- κ B translocation from cytoplasm into the nucleus, activating iNOS for NO accumulation and resulting in promotion of tumor progression by stimulating COX-2 expression [47]. High prostaglandin production by tumors results from upregulation of COX-2, which has been documented in several human cancers [48]. Chemotherapeutic or chemopreventive drugs able to inhibit both COX-2 and iNOS may become important adjuvants for inclusion in therapeutic protocols [2].

The effects of oxidants on signaling pathways are often characterized as resulting from oxidative stress. Our group reported that many antioxidants possessed anti-inflammatory effects. These findings provided a significant molecular basis for understanding the mode of actions of biochemically active dietary compounds in preventing cancer and inflammation. Figure 6 summarizes the roles of isovitexin during the process of carcinogenesis and inflammation and illustrates that isovitexin inhibited the LPS-induced NO and PGE₂ production in mouse macrophage RAW 264.7 cells (Fig. 3 and 4). Isovitexin displayed xanthine oxidase, an

intracellular enzymatic ROS source, inhibitory activity with blockade on its substrate-binding site [49]. PKC-activated xanthine oxidase activity upon LPS induction may be hampered by isovitexin which can reduce ROS generation in cells. Isovitexin possessed high antioxidant activity in previous studies [30], as well as in our own. Our findings demonstrate that isovitexin can block activation of NF- κ B by interfering with the phosphorylation of I κ B via its preventive effect on ROS generation and its ROS scavenger activity. Therefore, I κ B still binds to NF- κ B and prevents NF- κ B translocation from the cytoplasm into the nucleus (Fig. 5A). Recently, activation of p38 or ERK-1 and -2 has been shown to be involved in stimulation of NF- κ B activity and subsequent expression of iNOS and COX-2 in murine macrophages [50-52]. Protein tyrosine kinase has been implicated in NF- κ B activation by LPS, UV light and hypoxia [53]. Isovitexin might also inhibit these kinase activities, inhibiting NF- κ B activation upstream of the I κ B phosphorylation. Immunoblot analysis supports that the inhibition of NF- κ B activity by isovitexin might result from the inhibition of I κ B α phosphorylation, degradation, and then reduction of the translocation of NF- κ B subunits (Fig. 5A). However, isovitexin might also inhibit other signaling pathways induced by LPS which may be involved in the gene transcription of COX-2 and iNOS. Recently, our laboratories have also indicated that some flavonoids have the potential to inhibit the activity of IKK [54]. It remains to be elucidated if isovitexin correlates with suppression of IKK activity. Taken together, isovitexin is a food phytochemical in rice products that may play a role in the prevention of carcinogenesis and inflammation through suppressing NF- κ B activation.

References

- 1 Cuzzocrea S, Riley DP, Caputi AP, Salvemini D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. *Pharmacol Rev* 2001;53:135–59.
- 2 Fitzpatrick FA. Inflammation, carcinogenesis and cancer. *International Immunopharmacology* 2001;1:1651-67.
- 3 Pavlick KP, Laroux FS, Fuseler J, Wolf RE, Gray L, Hoffman J, Grisham MB. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. *Free Radic Biol Med* 2002;33:311-22.
- 4 Bowie A, O'Neill LAJ. Oxidative stress and nuclear factor- κ B activation: a reassessment of the evidence in the light of recent discoveries. *Biochem Pharmacol* 2000;59:13-23.
- 5 Crofford LJ, Wilder RL, Ristimaki AP, Sano H, Remmers EF, Epps HR, Hla T. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissue. Effects of interleukin-1 β , phorbol ester, and corticosteroids. *J Clin Invest* 1994;93:1095–101.
- 6 Inoue H, Yokoyama C, Hara S, Tone Y, Tanabe T. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. *J Biol Chem* 1995;270:24965-71.
- 7 Hla T, Ristimaki A, Appleby S, Barriocanal JG. Cyclooxygenase gene expression in inflammation and angiogenesis. *Ann NY Acad Sci* 1993;696:197–204.
- 8 Routledge MN, Wink DA, Keefer LK, Dipple A. DNA sequence changes induced by two nitric oxide donor drugs in the supF assay. *Chem Res Toxicol* 1994;7:628–32.
- 9 Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ, Bicknell R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. *J Clin Invest* 1997;99:2625–34.
- 10 Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. *THE LANCET Oncology* 2001;2:149–56.
- 11 Baeuerle PA, Baltimore D. I kappa B, A specific inhibitor of the NF-kappa B transcription factor. *Science* 1988;242:540-6.
- 12 Baeuerle PA, Baltimore D. NF-kappa B: ten years after. *Cell* 1996;87:13-20.
- 13 Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. *J Biol Chem* 1994;269:4705-8.
- 14 Jeon YJ, Kim YK, Lee M, Park SM, Han SB, Kim HM. Radicol suppresses expression of inducible nitric-oxide synthase by blocking p38 kinase and nuclear factor-kappaB/Rel in lipopolysaccharide-stimulated macrophages. *J Pharmacol Exp Ther* 2000;294:548-54.
- 15 Vincenti MP, Burrell TA, Taffet SM. Regulation of NF-kappa B activity in murine macrophages: effect of bacterial lipopolysaccharide and phorbol ester. *J Cell Physiol* 1992;150:204-13.

- 16 Feuillard J, Gouy H, Bismuth G, Lee LM, Debre P, Korner M. NF-kappa B activation by tumor necrosis factor alpha in the Jurkat T cell line is independent of protein kinase A, protein kinase C, and Ca(2+)-regulated kinases. *Cytokine* 1991;3:257-65.
- 17 Muroi M, Suzuki T. Role of protein kinase A in LPS-induced activation of NF-kappa B proteins of a mouse macrophage-like cell line, J774. *Cell Signa* 1993;5:289-98.
- 18 Kang JL, Go YH, Hur KC, Castranova V. Silica-induced nuclear factor-kappaB activation: involvement of reactive oxygen species and protein tyrosine kinase activation. *J Toxicol Environ Health A* 2000;60:27-46.
- 19 Kang JL, Pack IS, Lee HS, Castranova V. Enhancement of nuclear factor-kappaB activation and protein tyrosine phosphorylation by a tyrosine phosphatase inhibitor, pervanadate, involves reactive oxygen species in silica-stimulated macrophages. *Toxicology* 2000;151:81-9.
- 20 Kang JL, Pack IS, Hong SM, Lee HS, Castranova V. Silica induces nuclear factor-kappa B activation through tyrosine phosphorylation of I kappa B-alpha in RAW264.7 macrophages. *Toxicol Appl Pharmacol* 2000;169:59-65.
- 21 Lin YL, Lin JK. (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB. *Mol Pharmacol* 1997;52:465-72.
- 22 Tsai SH, Lin-Shiau SY, Lin JK. Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. *Br J Pharmacol* 1999;126:673-80.
- 23 Shi X, Ding M, Dong Z, Chen F, Ye J, Wang S, Leonard SS, Castranova V, Vallyathan V. Antioxidant properties of aspirin: characterization of the ability of aspirin to inhibit silica-induced lipid peroxidation, DNA damage, NF- kappaB activation, and TNF-alpha production. *Mol Cell Biochem* 1999;199:93-102.
- 24 Liang YC, Huang YT, Tsai SH, Lin-Shiau SY, Chen CF, Lin JK. Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. *Carcinogenesis* 1999;20:1945-52.
- 25 Koo LS, Mang OW, Ho JH. An ecological study of trends in cancer incidence and dietary changes in Hong Kong. *Nutr Cancer* 1997;28:289-301.
- 26 Yasukawa K, Akihisa T, Kimura Y, Tamura T, Takido M. Inhibitory effect of cycloartenol ferulate, a component of rice bran, on tumor promotion in two-stage carcinogenesis in mouse skin. *Biol Pharm Bull* 1998;21:1072-6.
- 27 Takeshita M, Nakamura S, Makita F, Ohwada S, Miyamoto Y, Morishita Y. Antitumor effect of RBS (rice bran saccharide) on ENNG-induced carcinogenesis. *Biotherapy* 1992;4:139-145.
- 28 Hayashi Y, Nishikawa Y, Mori H, Tamura H, Matsushita Y-I, Matsui T. Antitumour activity of (10E,12Z)-9-hydroxy-10,12-octadecadienoic acid from rice bran. *J Ferment Bioengineer* 1998;86:149-53.
- 29 Hudson EA, Dinh PA, Kokubun T, Simmonds MSJ, Gescher A. Characterization of potentially chemopreventive phenols in extracts of brown rice that inhibit the growth of human breast and colon cancer cells. *Cancer Epidemiol Biomarkers Prev* 2000;9:1163-70.
- 30 Ramarathnam N, Osawa T, Namiki M, Kawakishi S. Chemical studies on novel rice hull antioxidants. 2. Identification of isovitexin, a C-glycosyl flavonoid. *J Agric Food Chem* 1989;37:316-9.
- 31 Lin C-M, Chen C-T, Lee H-H, Lin J-K. Prevention of cellular ROS damage by isovitexin and related flavonoids. *Planta Medica* 2002;68:363-5.
- 32 Fiorentini G., et al .Amifostine (Ethyol) as modulator of hepatic and biliary toxicity from intraarterial hepatic chemoembolization: results of a phase I study. *Hepato-Gastroenterology*. 48(38):313-6, 2001 Mar-Apr.
- 33 Fiorentini G., et al .Amifostine (Ethyol) as modulator of hepatic and biliary toxicity from intraarterial hepatic chemoembolization: results of a phase I study. *Hepato-Gastroenterology*. 48(38):313-6, 2001 Mar-Apr.
- 34 . Wachowicz B ,Krajewski T, Olas B, Zbikowska HM.:Effects of cisplatin and selenite on the level of thiols in pig blood platelets. *Journal of physiology & Pharmacology*. 46(1): 97-103, 1995 Mar.
- 35 Olas B., Wachowicz B., Buczynski A. Adhesion of blood platelets to collagen and fibrinogen after treatment with cisplatin and its complex with glutathione. *Cytobios*. 102 (400): 75-84, 2000.
- 36 Rybak LP., Husain K., Whitworth C., Somani SM. Dose dependent protection by lipoic acid against cisplatin-induced ototoxicity in rats: antioxidant defense. *Toxicological Sciences*. 47 (2): 195-202, 1999 Feb.
- 37 Olas B., et al. The effect of cis-diammineedichloroplatinum, selenite and a conjugate of cisplatin with selenite [(NH₃)₂Pt(SeO₃)] on oxidative stress in blood platelets measured by chemiluminescence method. *Journal of Physiology & Pharmacology*. 50(2): 229-308, 1999 Jun.

- 39 Halliwell B. Effect of diet on cancer development: is oxidative DNA damage a biomarker? *Free Radic Biol Med* 2002;32:968-74.
- 40 Box HC, Freund HG, Budzinski E, Wallace JC, Maccubbin AE. Free radical-induced double base lesions. *Radiat Res* 1995;141:91-4.
- 41 Forman HJ, Torres M. Redox signaling in macrophages. *Mol Aspects Med* 2001;22:189-216.
- 42 Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, Goldschmidt-Clermont PJ. Mitogenic signaling mediated by oxidants in RAS-transformed fibroblasts. *Science* 1997;275:1649-52.
- 43 Lee SF, Huang YT, Wu WS, Lin JK. Induction of c-jun protooncogene expression by hydrogen peroxide through hydroxyl radical generation and p60^{src} tyrosine kinase activation. *Free Radic Biol Med* 1996;21:437-48.
- 44 Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. *EMBO J* 1991;10:2247-58.
- 45 Schmidt KN, Amstad P, Cerutti P, Baeuerle PA. The roles of hydrogen peroxide and superoxide as messengers in the activation of transcription factor NF-kappa B. *Chem Biol* 1995;2:13-22.
- 46 Cuzzocrea S, Chatterjee PK, Mazzon E, Dugo L, Serraino I, Britti D, Mazzullo G, Caputi AP, Thiemermann C. Pyrrolidine dithiocarbamate attenuates the development of acute and chronic inflammation. *Br J Pharmacol* 2002;135:496-510.
- 47 Lin JK, Lin-Shiau SY. Mechanisms of cancer chemoprevention by curcumin. *Proc Natl Sci Council ROC(B)* 2001;25:59-66.
- 48 Prescottte SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. *Biochem Biophys Acta* 2000;1470:M69-78.
- 49 Lin C-M, Chen C-S, Chen C-T, Liang Y-C, Lin J-K. Molecular modeling of flavonoids that inhibits xanthine oxidase. *Biochem Biophys Res Com* 2002;294:167-72.
- 50 Hwang D, Jang BC, Yu G, Boudreau M. Expression of mitogen-inducible cyclooxygenase induced by lipopolysaccharide: mediation through both mitogen-activated protein kinase and NF-kappaB signaling pathways in macrophages. *Biochem Pharmacol* 1997;54:87-96.
- 51 Ajizian SJ, English BK, Meals EA. Specific inhibitors of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways block inducible nitric oxide synthase and tumor necrosis factor accumulation in murine macrophages stimulated with lipopolysaccharide and interferon-gamma. *J Infect Dis* 1999;179:939-44.
- 52 Chen CC, Wang JK. p38 but not p44/42 mitogen-activated protein kinase is required for nitric oxide synthase induction mediated by lipopolysaccharide in RAW 264. 7 macrophages. *Mol Pharmacol* 1999;55:481-8.
- 53 Bastian NR, Hibbs JBJ. Assembly and regulation of NADPH oxidase and nitric oxidase synthase. *Curr Opin Immunol* 1994;6:131-9.
- 54 Tsai S-H, Liang Y-C, Lin-Shiau S-Y, Lin J-K. Suppression of TNF α -mediated NF- κ B activity by myricetin and other flavonoids through down regulating the activity of IKK in ECV304 cells. *J Cell Biochem* 1999;74:606-15.